CervoMed Inc. — Director's Dealing 2018

Oct 3, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2018-09-21

Reporting Person: Hornung William Karl (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.1800	2028-01-02	Common Stock (90000)		Direct

Footnotes

F1: The option was originally granted on January 2, 2018 and the underlying shares will vest in equal (or as near equal as possible) amounts on the last day of each month commencing January 31, 2018 until fully vested on December 31, 2020.